NCT04089527View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 24, 2019

Primary Completion Date

October 25, 2021

Study Completion Date

October 25, 2021

Conditions
Lymphoma, Non-Hodgkin
Interventions
DRUG

CC-95775

CC-95775

Trial Locations (5)

28050

Hospital de Madrid Norte- Sanchinarro, Madrid

31008

Clinica Universidad de Navarra, Pamplona

35200

Centre Eugene Marquis, Rennes

75005

Institut Curie, Paris

75010

Hopital Saint Louis, Paris

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT04089527 - Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter